Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$136.63 USD
-1.84 (-1.33%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $136.57 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Neurocrine Biosciences, Inc. has a market cap of $13.73B, which represents its share price of $138.47 multiplied by its outstanding shares number of 99.18M. As a large-cap company, NBIX's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NBIX 136.63 -1.84(-1.33%)
Will NBIX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS or NBIX: Which Is the Better Value Stock Right Now?
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for NBIX
Is NBIX likely to continue higher? Directional Movement Crossover Bullish shows up after sliding 0.44%
Neurocrine price target raised to $195 from $188 at UBS
Neurocrine price target raised by $7 at UBS, here's why
Is NBIX poised for gains? Crossed Above 50 Day Moving Average shows up after rising 1.52%
UBS Analyst Raises Price Target for Neurocrine Biosciences (NBIX) | NBIX Stock News